The company's ONETest platform enables accurate and simultaneous detection and discrimination of hundreds of pathogens, capturing actionable genomic data at par with meta-genomic sequencing at a fraction of the cost. The platform offers high sensitivity and specificity, detail pathogen data including virulence and resistance markers, and targets a high number of organisms and variants. Fusion Genomics develops tests for both the surveillance/research and clinical markets, with its present tests having gained traction in the surveillance market in Canada and the EU. The company's disruptive DNA and RNA capture technology, part of a "benchtop to desktop solution" called the ONETest platform, enables the comprehensive identification of pathogens from virtually any source in eight to twelve hours, offering 10,000x the sensitivity, accuracy across 20% genetics distance, and at one-tenth the cost.